Displaying drugs 11351 - 11375 of 11564 in total
MP4
MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.
Investigational
Matched Description: … MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. …
BMS-986104
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind …
Ontuxizumab
Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
Investigational
Matched Description: … Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 …
Cry5B
Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium Bacillus thuringiensis. With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]
Investigational
Matched Description: … Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis …
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo …
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected …
(1R,2S)-2-Phenylcyclopropanaminium
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. …
DNB-001
DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma. In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve.
Investigational
Matched Description: … DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed …
IC41
IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.
Investigational
Matched Description: … IC41 is a therapeutic peptide vaccine. …
Probiorinse
Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136. This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.
Investigational
Matched Description: … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation …
Prolectin-M
Prolectin-M is a (1-6)-alpha-D-mannopyranose and acts as an antagonist of galectin. It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Investigational
Matched Description: … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. …
Indisulam
Investigational
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Description: … ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms …
4-Phenylfentanyl
4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.
Illicit
Matched Description: … 4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency …
Natural Killer Cell
Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry...
Investigational
Matched Description: … leukapheresis: a technique where immune cells are separated from red blood cells. ... The most standard and utilized source of NK cells is directly from the peripheral blood of a donor through ... stem cells (iPSCs) and human embryonic stem cells (HESCs) are also used to generate NK cells through a …
Ubenimex
Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
Investigational
Matched Description: … Ubenimex (also known as bestatin) is a competitive protease inhibitor. …
IPH 1101
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Matched Description: … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens …
Odanacatib
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Investigational
Matched Description: … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment …
Foliglurax
Foliglurax is under investigation in clinical trial NCT02639221 (A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects).
Investigational
Matched Description: … Foliglurax is under investigation in clinical trial NCT02639221 (A Phase I, Double Blind, Placebo Controlled …
Mezigdomide
Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels …
SM-1997
SM-1997 is a protein-free solution derived from calf's blood comprising electrolytes, trace minerals, amino acids, peptides, nucleosides, and nucleotides. It is under investigation for the treatment of cutaneous sulfur mustard-induced injury.
Investigational
Matched Description: … SM-1997 is a protein-free solution derived from calf's blood comprising electrolytes, trace minerals, …
NS-3728
NS3728 is an orally active chloride channel blocker for the treatment of cancer.
Investigational
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Matched Description: … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease …
NBI-6024
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigational
Displaying drugs 11351 - 11375 of 11564 in total